CK-2127107
( DrugBank: CK-2127107 / KEGG DRUG: Reldesemtiv )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 2 | 筋萎縮性側索硬化症 | 13 |
2. 筋萎縮性側索硬化症
臨床試験数 : 645 / 薬物数 : 589 - (DrugBank : 163) / 標的遺伝子数 : 150 - 標的パスウェイ数 : 225
Showing 1 to 10 of 13 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2020-004040-29-PT (EUCTR) | 14/01/202220220114 | 20/05/202120210520 | A Clinical Study in which patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) will receive Reldesemtiv (study drug). The safety and efficacy of the drug will be tested. A Clinical Study in which patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) will receive R ... | A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS). - COURAGE-ALS A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy ... | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term ... | Product Name: reldesemtiv Product Code: CK-2127107 INN or Proposed INN: reldesemtiv Other descriptive name: RELDESEMTIV Product Name: reldesemtiv Product Code: CK-2127107 INN or Proposed INN: reldesemtiv Other descriptive n ... | Cytokinetics Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 555 | Phase 3 | Portugal;United States;Spain;Ireland;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Poland;Australia;Germany;Netherlands;Sweden Portugal;United States;Spain;Ireland;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Poland;A ... | ||
| 2 | EUCTR2020-004040-29-NL (EUCTR) | 25/11/202120211125 | 01/09/202120210901 | A Clinical Study in which patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) will receive Reldesemtiv (study drug). The safety and efficacy of the drug will be tested. A Clinical Study in which patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) will receive R ... | A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS). - COURAGE-ALS A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy ... | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term ... | Product Name: reldesemtiv Product Code: CK-2127107 INN or Proposed INN: reldesemtiv Other descriptive name: RELDESEMTIV Product Name: reldesemtiv Product Code: CK-2127107 INN or Proposed INN: reldesemtiv Other descriptive n ... | Cytokinetics Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 555 | Phase 3 | United States;Portugal;Spain;Ireland;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Poland;Australia;Netherlands;Germany;Sweden United States;Portugal;Spain;Ireland;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Poland;A ... | ||
| 3 | EUCTR2020-004040-29-ES (EUCTR) | 05/10/202120211005 | 21/06/202120210621 | A Clinical Study in which patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) will receive Reldesemtiv (study drug). The safety and efficacy of the drug will be tested. A Clinical Study in which patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) will receive R ... | A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS). - COURAGE-ALS A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy ... | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term ... | Product Name: reldesemtiv Product Code: CK-2127107 INN or Proposed INN: reldesemtiv Other descriptive name: RELDESEMTIV Product Name: reldesemtiv Product Code: CK-2127107 INN or Proposed INN: reldesemtiv Other descriptive n ... | Cytokinetics Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 555 | Phase 3 | United States;Portugal;Spain;Ireland;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Poland;Australia;Germany;Netherlands;Sweden United States;Portugal;Spain;Ireland;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Poland;A ... | ||
| 4 | EUCTR2020-004040-29-IT (EUCTR) | 20/09/202120210920 | 30/08/202120210830 | A Clinical Study in which patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) will receive Reldesemtiv (study drug). The safety and efficacy of the drug will be tested A Clinical Study in which patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) will receive R ... | A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS) - COURAGE-ALS A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy ... | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term ... | Product Name: reldesemtiv Product Code: [CK-2127107] INN or Proposed INN: reldesemtiv | CYTOKINETICS, INC. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 555 | Phase 3 | United States;Portugal;Spain;Ireland;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Poland;Australia;Germany;Netherlands;Sweden United States;Portugal;Spain;Ireland;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Poland;A ... | ||
| 5 | EUCTR2020-004040-29-SE (EUCTR) | 07/09/202120210907 | 01/06/202120210601 | A Clinical Study in which patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) will receive Reldesemtiv (study drug). The safety and efficacy of the drug will be tested. A Clinical Study in which patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) will receive R ... | A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS). - COURAGE-ALS A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy ... | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term ... | Product Name: reldesemtiv Product Code: CK-2127107 INN or Proposed INN: reldesemtiv Other descriptive name: RELDESEMTIV Product Name: reldesemtiv Product Code: CK-2127107 INN or Proposed INN: reldesemtiv Other descriptive n ... | Cytokinetics Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 555 | Phase 3 | United States;Portugal;Spain;Ireland;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Poland;Australia;Germany;Netherlands;Sweden United States;Portugal;Spain;Ireland;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Poland;A ... | ||
| 6 | EUCTR2020-004040-29-IE (EUCTR) | 02/07/202120210702 | 09/04/202120210409 | A Clinical Study in which patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) will receive Reldesemtiv (study drug). The safety and efficacy of the drug will be tested. A Clinical Study in which patients diagnosed with Amyotrophic Lateral Sclerosis (ALS) will receive R ... | A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients with Amyotrophic Lateral Sclerosis (ALS). - COURAGE-ALS A Phase 3, Multi-center, Double Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy ... | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 21.1;Level: PT;Classification code 10002026;Term ... | Product Name: reldesemtiv Product Code: CK-2127107 INN or Proposed INN: reldesemtiv Other descriptive name: RELDESEMTIV Product Name: reldesemtiv Product Code: CK-2127107 INN or Proposed INN: reldesemtiv Other descriptive n ... | Cytokinetics Inc | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 555 | Phase 3 | United States;Portugal;Spain;Ireland;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Poland;Australia;Germany;Netherlands;Sweden United States;Portugal;Spain;Ireland;United Kingdom;Switzerland;Italy;France;Canada;Belgium;Poland;A ... | ||
| 7 | EUCTR2018-000586-37-IE (EUCTR) | 13/09/201820180913 | 08/05/201820180508 | A Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 In Patients with Amyotrophic Lateral Sclerosis (ALS) A Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107In Patients with Amyotrophic ... | A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability Of CK-2127107 In Patients with Amyotrophic Lateral Sclerosis (ALS) A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluat ... | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 20.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 20.0;Level: PT;Classification code 10002026;Term ... | Product Name: Reldesemtiv Product Code: CK-2127107 INN or Proposed INN: Reldesemtiv Other descriptive name: Reldesemtiv Product Name: Reldesemtiv Product Code: CK-2127107 INN or Proposed INN: Reldesemtiv Other descriptive n ... | Cytokinetics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 445 | Phase 2 | United States;Canada;Spain;Ireland;Australia;Netherlands | ||
| 8 | EUCTR2018-000586-37-NL (EUCTR) | 15/08/201820180815 | 04/06/201820180604 | A Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 In Patients with Amyotrophic Lateral Sclerosis (ALS) A Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107In Patients with Amyotrophic ... | A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability Of CK-2127107 In Patients with Amyotrophic Lateral Sclerosis (ALS) A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluat ... | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 20.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 20.0;Level: PT;Classification code 10002026;Term ... | Product Name: Reldesemtiv Product Code: CK-2127107 INN or Proposed INN: Reldesemtiv Other descriptive name: Reldesemtiv Product Name: Reldesemtiv Product Code: CK-2127107 INN or Proposed INN: Reldesemtiv Other descriptive n ... | Cytokinetics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 445 | Phase 2 | United States;Canada;Spain;Ireland;Australia;Netherlands | ||
| 9 | EUCTR2018-000586-37-ES (EUCTR) | 19/07/201820180719 | 23/05/201820180523 | A Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 In Patients with Amyotrophic Lateral Sclerosis (ALS) A Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107In Patients with Amyotrophic ... | A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability Of CK-2127107 In Patients with Amyotrophic Lateral Sclerosis (ALS) A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluat ... | Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 20.0;Level: PT;Classification code 10002026;Term: Amyotrophic lateral sclerosis;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] Amyotrophic Lateral Sclerosis (ALS) MedDRA version: 20.0;Level: PT;Classification code 10002026;Term ... | Product Name: Reldesemtiv Product Code: CK-2127107 INN or Proposed INN: Reldesemtiv Other descriptive name: Reldesemtiv Product Name: Reldesemtiv Product Code: CK-2127107 INN or Proposed INN: Reldesemtiv Other descriptive n ... | Cytokinetics, Inc. | NULL | Not Recruiting | Female: yes Male: yes | 445 | Phase 2 | United States;Canada;Spain;Ireland;Australia;Netherlands | ||
| 10 | NCT03160898 (ClinicalTrials.gov) | July 24, 201720170724 | 12/5/201720170512 | A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107in Patients With Amyotrophic Late ... | A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) A Phase 2, Multi-Center, Double-Blind, Randomized, Dose-Ranging, Placebo-Controlled Study to Evaluat ... | Amyotrophic Lateral Sclerosis | Drug: Reldesemtiv;Drug: Placebo | Cytokinetics | Astellas Pharma Inc | Completed | 18 Years | 80 Years | All | 458 | Phase 2 | United States;Australia;Canada;Ireland;Netherlands;Spain |